1. AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. (February 2019) Authors: Iavarone, M.; Galmozzi, E.; De Silvestri, A.; Casadei-Gardini, A.; Piscaglia, F.; Marisi, G.; Facchetti, F.; Faloppi, L.; Ielasi, L.; Tovoli, F.; Cimino, A.; Scartozzi, M.; Cascinu, S.; Sangiovanni, A.; Tinelli, C.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma. (March 2023) Authors: Ielasi, L.; Tovoli, F.; Stefanini, B.; Tortora, R.; Magini, G.; Sacco, R.; Pressiani, T.; Trevisani, F.; Piscaglia, F.; Granito, A. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prognostic impact of previous intraarterial treatment in patients with hcc treated with sorafenib. (March 2023) Authors: Stefanini, B.; Ielasi, L.; Pressiani, T.; Trevisani, F.; Sacco, R.; Gardini, A. Casadei; Magini, G.; Di Costanzo, G.G.; Granito, A.; Tovoli, F.; Piscaglia, F. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model. (February 2020) Authors: Sansone, V.; Tovoli, F.; Casadei-Gardini, A.; Di Costanzo, G.G.; Magini, G.; Sacco, R.; Pressiani, T.; Trevisani, F.; Tortora, R.; Ielasi, L.; Granito, A. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗